Building Standardized ctDNA & MRD Strategies to Accelerate Clinical Development of Immune-Based Therapies
- Examining how ctDNA and MRD assays can serve as regulatory-acceptable biomarkers and support commercialization of CAR-T and T-cell engager therapies
- Addressing harmonization challenges across assay platforms and how standardization can streamline late-phase trials and companion diagnostic development
- Exploring opportunities for integrated, multi-omic bloodbased assays to provide scalable solutions that meet payer, regulatory, and clinician expectations